Compare PHARMENA SA with Similar Stocks
Dashboard
1
High Debt Company with a Debt to Equity ratio (avg) at times
- Poor long term growth as Net Sales has grown by an annual rate of -51.62% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- The company has been able to generate a Return on Equity (avg) of 23.51% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of -51.62% over the last 5 years
3
Flat results in Sep 24
4
Risky -
5
Consistent Underperformance against the benchmark over the last 3 years
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
31.37%
0%
31.37%
6 Months
-6.42%
0%
-6.42%
1 Year
-26.54%
0%
-26.54%
2 Years
-58.74%
0%
-58.74%
3 Years
-43.98%
0%
-43.98%
4 Years
-46.74%
0%
-46.74%
5 Years
-71.61%
0%
-71.61%
PHARMENA SA for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-51.62%
EBIT Growth (5y)
9.46%
EBIT to Interest (avg)
-3.92
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.91
Sales to Capital Employed (avg)
2.25
Tax Ratio
31.25%
Dividend Payout Ratio
32.71%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
23.51%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.18
EV to EBIT
-8.43
EV to EBITDA
-8.73
EV to Capital Employed
26.03
EV to Sales
26.58
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-309.01%
ROE (Latest)
-14.34%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bearish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'23
Change(%)
Net Sales
1.60
0.30
433.33%
Operating Profit (PBDIT) excl Other Income
-3.20
-3.70
13.51%
Interest
0.00
0.50
-100.00%
Exceptional Items
0.00
-0.00
Consolidate Net Profit
-2.80
27.00
-110.37%
Operating Profit Margin (Excl OI)
-2,080.50%
-13,448.20%
1,136.77%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 433.33% vs 0.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -110.37% vs 619.23% in Dec 2023
About PHARMENA SA 
PHARMENA SA
FMCG
Pharmena SA is a Poland-based producer of cosmetics and pharmaceuticals. The Company’s products range encompasses Dermena, a line of products against hair loss; Dermena Plus, a shampoo reducing the symptoms of dandruff and preventing excessive hair loss; Accos, an anti-acne gel; Allerco, a line of hypo-allergic emollients for body care, Thermi, a gel after thermal burn and sunburn; and Revium, a line of anti-wrinkle treatment products. Pharmena SA maintains multidirectional research works and application studies in conjunction with a number of research centers in Europe, the United States and Canada. As of December 31, 2011, the Company had one wholly owned subsidiary, Cortria Corporation, based in the United States. As of December 31, 2011, Polska Grupa Farmaceutyczna SA held a 43.65% stake in the capital. The main shareholder of the Company is Pelion SA.
Company Coordinates 
Company Details
Ul. Wolczanska 178 , LODZ None : 90-530
Registrar Details






